Summary: Roche and Microsoft be a part of forces in Egypt, Sunrise secures 6.5 million euros for a sleep apnea resolution and additional briefings

Roche and Microsoft join forces to improve healthcare in Egypt

Roche and Microsoft have signed a Memorandum of Understanding (MoU) to improve patient care outcomes with artificial intelligence (AI) and cloud technology.

The MoU will be implemented in Egypt with a roadmap to roll out the concept in the Middle East, including Egypt, KSA, UAE, Kuwait, Oman, Bahrain, Qatar, Lebanon, Jordan, Iraq and Syria.

Through the collaboration, the two companies will explore third-party technology and AI solutions to optimize patient travel beyond treatment and support early diagnosis.

Dr. Mohamed Swilam, General Manager of Roche Egypt, said, “The power of technology, data and analytics can rejuvenate the healthcare ecosystem and improve patient outcomes in unprecedented ways.”

Healthtech startup Sunrise collects 6.5 million euros for a sleep apnea solution

Belgian health technology company Sunrise has closed a 3.25 million dollar

Sunrise plans to launch and market internationally its first diagnostic product for sleep apnea, which uses a 3 gram sensor in conjunction with artificial intelligence (AI).

In addition to the financing round, 3.25 million euros are available in non-dilutive funding from the European Innovation Council and the Walloon .

Sunrise CEO and co-founder Laurent Martinot: “We have the measurement of a new biosignal: We analyze lower jaw movements while sleeping. The sensor communicates with a mobile application. The collected data is processed thanks to AI and can be sent to the doctor the next morning, which saves time and makes diagnosis easier. “

Iktos and the University of Dundee cooperate in the development of drugs against tropical diseases

Drug design company Iktos has announced a collaboration with the University of Dundee’s Drug Discovery Unit (DDU) to identify therapeutics for tropical diseases affecting the world’s poorest people.

The university will apply Iktos’ de novo ligand and structure-based generative modeling technologies, the AI-based retrosynthesis analysis and planning tool SpayaTM to identify potential preclinical candidates and additional novel chemicals with suitable properties.

Professor Paul Wyatt, Head of DDU, said: “We are very excited to be working with Iktos to advance our drug candidate projects. Iktos’ AI platform combined with our own computer and medicinal chemistry design teams provide a powerful combination for innovative new drug design. “

MedTech Europe welcomes changes to the transitional provisions of the IVD regulation

The trade association MedTech Europe has welcomed the adoption of the European Commission’s proposal to amend the transitional provisions of the new EU regulation for in-vitro diagnostics (IVD) for medical devices.

The change mitigates the that medical tests for all clinical areas in the market, including those that detect COVID-19, will no longer be available as of May 2022.

Serge Bernasconi, CEO of MedTech Europe, said: “The decision to change the transitional provisions of the IVD regulation comes at the last moment to ensure that medical tests can remain available to Europe’s patients and healthcare systems.

“It is now important that regulators address the remaining critical issues that support certification ahead of the new deadlines of more than 32,000 medical tests on the market today, as well as certification of innovative diagnostics that are in the pipeline are and will. “respond to unmet medical needs.”

Leave a comment

Your email address will not be published. Required fields are marked *